drugset / Trial / NCT02862431

Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-64565111 in Type 2 Diabetes Mellitus (T2DM)

NCT02862431

Phase 1 Terminated 24 enrolled Janssen Research & Development, LLC
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to assess the safety and tolerability of JNJ-64565111 in adult Men and Women (of non-child bearing potential) with Type 2 Diabetes Mellitus.

Timeline

Start
2016-07-12
Primary completion
2016-11-29
Completion
2016-12-05

Drugs

EvaluationDrugModalityDoseRoute
Subject JNJ-64565111 Unknown 2.5 mmol Subcutaneous
Subject JNJ-64565111 Unknown 3 mmol Subcutaneous
Subject JNJ-64565111 Unknown 3.5 mmol Subcutaneous